Tissue Microarray Market Size

Global Tissue Microarray Market Overview

Tissue Microarray Market Size was valued at USD 11.18 Billion in 2023. The Global Tissue Microarray industry is projected to grow from USD 12.30 Billion in 2024 to USD 26.47 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.11% during the forecast period (2024 - 2032).

Tissue microarray is paraffin blocks where up to 1000 separate cylindrical tissue cores can be assembled in an array fashion which allows analyzing of molecules that are present n DNA, mRNA, and protein levels under similar standardized conditions on a single glass slide. This versatile strategy where data automated analysis provides prospective and retrospective human tissue studies.

The rising applications in discovery of drugs, the increasing advancements in pharmaceutical companies and biotechnology, rising generality of cancer, and increasing demand for accurate and cost-effective diagnostic methods are the major factor that is contributing to the growth of the tissue microarray market. Array-based technology offers platforms for profiling of tissues such as DNA array and tissue array and disease genes; thousand of genres have been identified with the help of tissue microarray technology which can be associated with progression, initiation, and development. Moreover, tissue microarray is not beneficial for heterogeneous cancers and it is likely to create hurdles in the growth of the tissue microarray market.

This report contains all the information on the global tissue microarray market dynamics research and market strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other important factors. And a detailed analysis of the tissue microarray market and forecast to 2032 is also included in the report.

Covid 19 Analysis

The outbreak of the covid 19 viruses has spread to nearly almost every country around the globe, based on the reports of the World Health Organization (WHO) has declared a global pandemic. Based on researches, the outperformers are seeking growth in core expansion, geographic, adjacent spaces, and up and down the value chain.

Tissue Microarray Market Dynamics

Drivers

The rise in the number of cases of a cancer patient and the advancement of technology and the adoption of microarray technique in proteomics and genomics due to its requirement of the fewer samples, uniformity in results, and the rapid assay is likely to drive the tissue microarray market trends.

Opportunities

The rise in the usage of microarray in several applications is likely to create various opportunities for key players for the market to propel the tissue microarray market growth during the forecast period.

Restraints

The involvement of high cost in microarray techniques and availability of alternative techniques such as PCR is estimated to create hurdles in the growth of the tissue microarray market during the forecast period.  

Challenges

The identification of genres has intensified the process of lead discovery, clinical assessment of such leads can be considered as a challenging task due to the availability of several well-characterized tissue specimens. Tissue microarray simultaneously uses the array format to analyze thousand of tissue samples. The technique of tissue microarray helps in maintains the pace with the process of lead discovery.

Cumulative Growth Analysis

The generality of cancer is a crucial factor that contributes to the growth of the tissue microarray market. According to the reports of the American Cancer Society, in the year 2017, near about 13% of all cancer diagnosed in adults aged 20, in the report it is further stated that liver cancer, melanoma, and thyroid cancer rates are rising from the last few years. According to the reports of US Breast Cancer Statistics, about 1 in every 8 women which are about 12% is likely to develop invasive breast cancer throughout their lifetime. In the year 2017, there were about 252,710 estimated new breast cancer cases were predicted to diagnosed in women in the United States and there was 63,410 new non-invasive breast cancer were discovered.

Value Chain Analysis

According to the reports, the tissue microarray market has been segmented on the basis of procedure, technology, application, end-users, and regions. On the basis of procedure, the tissue microarray market has been segmented into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array. On the basis of technology, the tissue microarray market has been segmented into DNA microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting. On the basis of application, the market is divided into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics. On the basis of end-user, the tissue microarray market has been divided into pharmaceutical and biotechnological companies and research organizations. The research organization segment holds the maximum share in the market with a market value of USD 1876.02 Million in the year 2016.

Tissue Microarray Market Segmentation

The market is segmented on the basis of the tissue microarray procedure, technology, application, end-users, and regions. The tissue microarray market is expected to witness decent growth during the forecast period.

By Application

Based on the application, the market is segmented into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics

By end-users

Based on the propulsion types, the market is segmented into pharmaceutical and biotechnological companies and research organizations.

Tissue Microarray Market Regional Analysis

According to the reports, on the basis of region the tissue microarray market has been segmented into the Americas, Europe, Asia-pacific, and the Middle East & Africa. America is predicted to dominate the tissue microarray market during the forecast period due to the rise in the prevalence of cancer in the Americas which is ultimately leading to the rise in demand for the tissue microarray in this region. Moreover, the rising application in the discovery of drugs is also favorable for the growth of the tissue microarray market.

Europe is predicted to hold the second-largest share in the tissue microarray market due to rising emphasis on the treatment of cancer and its diagnosis, and infectious diseases. The change in lifestyle and rising prevalence of cancer among the rising population is likely to further boost the demand for the tissue microarray market in this region.

Competitive landscape

The key companies that are operating in the global market are highly focused on acquisitions and mergers which are predicted to support the growth of the tissue microarray market industry. The Asia Pacific is the fastest-growing region due to the high prevalence of cancer and changes in the lifestyle of developing countries of this region.

Major Key Players

•         Agilent Technologies


•         Illumina, Inc.


•         Protein Biotechnologies Inc.


•         Asterand Bioscience


•         Pantomics Inc.


•         Applied Microarrays


•         Arrayit


•         Phalanx Biotech


•         QIAGEN


•         Takara Bio


•         Perkin Elmer


•         Merck Sharp & Dohme Corp.

Report Overview

The following report comprises of –

•         Market overview 


•         Covid 19 Analysis


•         Market Dynamic


•         Drivers


•         Opportunities


•         Restraints 


•         Challenges


•         Cumulative Growth Analysis


•         Value Chain Analysis


•         Segmentation Overview 


•         By Application 


•         By End-Users


•         Regional Analysis


•         Competitive landscape

Recent Developments

• In January 2017, Agilent technologies announced its collaboration with the Centre for Human Genetics of the University of Leuven and the University Hospital of Leuven in Belgium.


• In July 2017, Horizon Discovery Group agreed to acquire GE Healthcare Dharmacon from parent General Electric for $85 million, creating a combined company focused on applying gene-editing and gene-modulation technologies in life science research.


• In January 2017, Illumina Inc. announced the launch of a Single-Cell Sequencing Solution in collaboration with Bio-Rad. It is the first Next-Generation Sequencing (NGS) workflow for single-cell analysis providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

Market Segmentation

By Procedure

• Immunohistochemistry


• Fluorescent in Situ Hybridization


• Frozen Tissue Array

By Technology

• DNA Microarray


• Polymerase Chain Reaction (PCR)


• Next-Generation Sequencing


• Northern Blotting


• Western Blotting

By Application

• Oncology


• Gene Expression Profiling


• SNP Detection


• Double-Stranded B-DNA Microarrays


• Comparative Genomic Hybridization


• Sequencing Bioinformatics

By End-user

• Pharmaceutical and Biotechnological Companies


• Research Organization

By Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • UK
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa